Posted by Larry Hoover on October 19, 2005, at 6:37:21
In reply to NRP104 - D-amphetamine bonded with Lysine?, posted by tecknohed on October 16, 2005, at 7:44:19
I did a little poking around about this new drug, and yes, it will avoid Schedule 2. The FDA has already determined that NRP104 is not an amphetamine/analog.
This drug is one of a series of investigational drugs, all falling under the registered mark of Conditionally Bioreversible Derivatives, known collectively as Carrierwave technology.
This lysine/amphetamine dimer must have a very simple structure. There's only one possible bond between the two, to form the conjugate, an amide bond at the lysine carboxylic moiety and the amphetamine amine.
The "condition" which would cleave the two would be low pH in the stomach, via acid catalyzed hydrolysis. Unless there is an enzyme specific to removing n-terminal lysine residues, I think that any inference that the release of amphetamine is under enzymatic control is quite specious. Certainly, intravenous or inhaled drug would fail to encounter the acidity required to hydrolyze the dimer at any substantial rate, so abuse potential would simply be via excessive oral intake.
IMHO, the release of amphetamine would be somewhat slower than from amphetamine salts, but not delayed release in any meaningful way.
That's just my brain looking at it, anyway.
Lar
poster:Larry Hoover
thread:567520
URL: http://www.dr-bob.org/babble/20051017/msgs/568781.html